Occurrence and Antimicrobial Susceptibility of Major Bacterial Pathogens Associated with Subclinical Mastitis in Dairy Cows in Western Romania

罗马尼亚西部奶牛亚临床乳腺炎相关主要致病菌的发生情况及抗菌药物敏感性

阅读:1

Abstract

Subclinical mastitis is a major but often overlooked constraint to dairy productivity, causing economic losses through reduced milk yield and quality. In Romania, comprehensive data on the bacterial etiology and antimicrobial resistance (AMR) of subclinical mastitis are limited. This study aimed to characterize the etiological agents and antimicrobial susceptibility profiles of major bacterial pathogens isolated from subclinical mastitis cases in dairy cows from Western Romania. Between 2021 and 2022, milk samples were collected from 117 lactating cows diagnosed with subclinical mastitis on three dairy farms. Bacterial isolation and differentiation were performed on ChromID(®) CPS(®) Elite Agar, and isolates were confirmed by standard biochemical tests. Antimicrobial susceptibility testing of Staphylococcus aureus and Escherichia coli isolates was conducted using the automated Vitek(®)2 system, interpreted according to CLSI veterinary standards. Multidrug resistance (MDR) was defined as resistance to at least one agent in three or more antimicrobial classes. Bacterial growth occurred in 51 of 117 samples (43.6%). S. aureus subsp. aureus predominated (28.2%), followed by E. coli (4.3%), Klebsiella pneumoniae subsp. pneumoniae (2.3%), and Streptococcus uberis (2.3%). Mixed infections occurred in 6.0% of positive samples. Among S. aureus, the highest resistance rates were to fosfomycin (58.3%), penicillin (44.4%), clindamycin (44.4%), and tetracycline (41.7%), with 47.2% MDR isolates. E. coli showed resistance to amoxicillin/clavulanic acid (88.9%), ampicillin (55.6%), and cefotaxime (55.6%), with 66.6% MDR. S. aureus remains the leading cause of subclinical mastitis in Western Romania. The high MDR rates highlight the need for targeted antimicrobial stewardship, culture-based therapy, and continuous AMR monitoring under the "One Health" framework.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。